Estriol therapy for multiple sclerosis and other autoimmune diseases
View Patent ↗The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis.
1. A method of treating a human exhibiting at least one clinical sign or symptom of multiple sclerosis, comprising administering estriol orally at about 4 milligrams to about 16 milligrams per day to ameliorate at least one sign or symptom of multiple sclerosis.
2. The method of claim 1 , wherein the estriol is estriol succinate or estriol sulfamate.
3. The method of claim 1 , comprising administering about 8 milligrams of estriol per day.
4. The method of claim 1 , wherein treatment results in patient serum concentrations of estriol of about 2 to about 30 nanograms per milliliter.
5. The method of claim 1 , wherein treatment results in patient serum concentrations of estriol of about 20 to about 30 nanograms per milliliter.
6. The method of claim 1 , wherein the treatment results in serum levels of estriol substantially similar to those of a woman in the mid second trimester through the end of the third trimester of pregnancy.
7. The method of claim 1 , further comprising administering at least one secondary agent at a therapeutically effective dosage in an effective dosage form at a predetermined interval.
8. The method of claim 7 , wherein the secondary agent is administered orally.
9. The method of claim 7 , wherein the secondary agent is administered by injection.
10. The method of claim 7 , wherein the secondary agent is administered subcutaneously.
11. The method of claim 7 , wherein the secondary agent is administered intramuscularly.
12. The method of claim 7 , wherein the secondary agent is progesterone.
13. The method of claim 12 , wherein progesterone is administered at a dose of about 100 to about 200 milligrams per day.
14. The method of claim 7 , wherein the secondary agent is a glucocorticoid.
15. The method of claim 14 , wherein the glucocorticoid is prednisone or methyl prednisone.
16. The method of claim 15 , wherein the glucocorticoid is prednisone and the prednisone is administered at a dose of about 5 to about 60 milligrams per day.
17. The method of claim 15 , wherein the glucocorticoid is methyl prednisone and the methyl prednisone is administered at a dose of about 1 to about 2 milligrams per day.
18. The method of claim 7 , wherein the secondary agent is a β-interferon.
19. The method of claim 18 , wherein the β-interferon is interferon β-1a or interferon β-1b.
20. The method of claim 19 , wherein the β-interferon is interferon β-1b and the interferon β-1b is administered at a dose of about 0.25 mg or less every other day.
21. The method of claim 19 , wherein the β-interferon is interferon β-1a and the interferon β-1a is administered at a dose of about 40 mcg to about 50 mcg three times per week.
22. The method of claim 19 , wherein the β-interferon is interferon β-1a and the interferon β-1a is administered at a dose of about 20 mcg to about 30 mcg once per week.
23. A method of treating a patient exhibiting at least one clinical sign or symptom of multiple sclerosis, comprising administering estriol orally at a dose of about 4 milligrams to about 16 milligrams each day and administering a secondary agent, wherein the administration of estriol and the secondary agent ameliorates the clinical sign or symptom.
24. The method of claim 7 , wherein the secondary agent is glatiramer acetate copolymer-1.
25. The method of claim 24 , wherein the glatiramer acetate copolymer-1 is administered at a dose of about 40 mg three times per week.